Rationale and design of the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE)

Diabetes Care

Volumn 36, Issue 8, 2013, Pages 2254-2261

  Nathan, David M ^a   Buse, John B ^b   Kahn, Steven E ^c   Krause Steinrauf, Heidi ^d   Larkin, Mary E ^a   Staten, Myrlene ^e   Wexler, Deborah ^a   Lachin, John M ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLARGINE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN; PYRAZINE DERIVATIVE; SULFONYLUREA DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARALLEL DESIGN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; AGONISTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ECONOMICS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

ADULT; BLOOD GLUCOSE; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PYRAZINES; SULFONYLUREA COMPOUNDS; TRIAZOLES;

EID: 84884550328     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0356     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. National diabetes fact sheet, 2011 [Internet]. Available from http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011. pdf. Accessed 25 January 2013
2. Nathan DM. Long-term complications of diabetes mellitus. N Engl JMed 1993;328: 1676-1685
3. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of onemillion U.S. adults. Diabetes Care 2012;35:1835-1844
4. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012 [article online], 2013. Available from http://care.diabetesjournals.org/ content/early/2013/03/05/dc12-2625.full.pdf+html. Accessed 8 May 2013
5. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-2094
6. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
7. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350
8. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986
10. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
11. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
12. Nathan DM. Clinical review 146: the impact of clinical trials on the treatment of diabetesmellitus. J Clin Endocrinol Metab 2002;87:1929-1937
13. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetesmellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009;119:1728-1735
14. Nathan DM. Finding new treatments for diabetesdhow many, how fast... how good? N Engl J Med 2007;356:437-440
15. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patientcentered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
16. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52: 17-30
17. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes. Can J Diabetes 2008;32(Suppl. 1): S53-S61
18. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559
19. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012;156:218-231
20. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443
21. Ryan DH, Espeland MA, Foster GD, et al.; Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610-628
22. Collins F. The CER vision of tomorrow: tailoring medicine to the individual. Presented at the Comparative Effectiveness and Personalized Medicine: An Essential Interface Conference, 19-20 October 2010, at the National Institutes of Health, Bethesda, Maryland
23. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 2010;95:1566-1574
24. Colagiuri S, Cull CA, Holman RR; UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care 2002;25:1410-1417
25. Kooy A, de Jager J, Lehert P, et al. Longterm effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch InternMed 2009;169:616-625
26. Desai NR, Shrank WH, Fischer MA, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012;125: 302.e1-302.e7
27. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011;34:1369-1371
28. Nauck M, Frid A, Hermansen K, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 2013;15: 204-212
29. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30:1979-1987
30. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallelgroup, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
31. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses ofmetformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23: 736-742
32. American Diabetes Association. Standards of medical care in diabetesd2013. Diabetes Care 2013;36(Suppl. 1):S11-S66
33. Lachin JM. Biostatistical Methods: The Assessment of Relative Risks. 2nd ed. New York, John Wiley and Sons, 2011
34. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1989;6:65-70
35. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22
36. Demidenko E. Mixed Models: Theory and Applications. New York, John Wiley and Sons, 2004
37. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079-1087
38. Lachin JM. Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med 1992;11:1151-1170
39. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986;42:507-519
40. Lachin JM, Viberti G, Zinman B, et al.; ADOPT Study Group. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol 2011;6:1032-1040